🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 22 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/01/2019 9,51 10,37 9,45 10,17 +7,05% 9,72% 133.800
30/01/2019 9,12 9,54 8,98 9,50 +5,20% 6,14% 89.900
29/01/2019 9,51 9,58 9,01 9,03 -4,65% 5,94% 73.000
28/01/2019 10,10 10,10 9,45 9,47 -7,61% 6,44% 56.000
25/01/2019 9,46 10,53 9,46 10,25 +9,51% 11,31% 122.400
24/01/2019 9,41 9,63 9,22 9,36 -0,74% 4,36% 53.800
23/01/2019 9,68 10,02 9,26 9,43 -2,08% 7,84% 72.400
22/01/2019 9,98 10,32 9,49 9,63 -4,18% 8,32% 71.000
18/01/2019 10,25 10,56 9,94 10,05 -1,47% 6,05% 66.600
17/01/2019 10,23 10,47 9,99 10,20 -1,54% 4,68% 133.500
16/01/2019 9,89 10,48 9,74 10,36 +5,71% 7,48% 136.400
15/01/2019 9,16 9,99 8,75 9,80 +8,05% 13,54% 159.000
14/01/2019 9,92 10,04 9,05 9,07 -9,21% 9,98% 96.700
11/01/2019 9,92 10,10 9,62 9,99 +0,20% 4,84% 115.200
10/01/2019 9,97 10,42 9,80 9,97 -1,48% 6,22% 166.800
09/01/2019 9,91 10,29 9,50 10,12 +2,53% 7,97% 107.200
08/01/2019 9,70 9,95 9,27 9,87 +2,71% 7,01% 123.100
07/01/2019 9,10 9,73 8,94 9,61 +7,37% 8,68% 929.700
04/01/2019 10,10 10,10 8,57 8,95 -14,11% 15,15% 537.500
03/01/2019 10,62 10,81 10,26 10,42 -2,43% 5,18% 172.900
02/01/2019 10,55 10,91 10,30 10,68 -0,84% 5,78% 431.900
31/12/2018 10,85 10,85 10,16 10,77 +0,47% 6,36% 194.900
28/12/2018 9,74 10,95 9,74 10,72 +9,84% 12,42% 274.100
27/12/2018 10,32 10,60 9,30 9,76 -7,84% 12,60% 242.900
26/12/2018 10,09 10,84 9,96 10,59 +6,01% 8,72% 201.700
24/12/2018 9,70 10,54 9,17 9,99 +1,63% 14,12% 110.400
21/12/2018 10,09 10,10 9,50 9,83 -1,80% 5,95% 2.512.300
20/12/2018 10,67 10,76 9,90 10,01 -7,31% 8,06% 272.500
19/12/2018 10,77 11,30 10,34 10,80 -1,55% 8,91% 289.000
18/12/2018 11,87 12,04 10,80 10,97 -7,19% 10,45% 625.800